Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Cerliponase Alfa Coverage Update | Op…
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy RX501.092

    Cerliponase alfa

    Customize your policy alerts

    Sign up for healthspring Policy RX501.092 alerts

    Get alerted when Policy RX501.092 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HealthSpring coverage and authorization considerations for cerliponase alfa. Coverage is subject to evidence of effectiveness, authoritative drug-therapy recommendations, applicable state requirements, and the member's benefit contract.

    Policy Summary
    PayerHealthSpring
    PolicyCerliponase alfa
    Policy CodePolicy RX501.092
    Change TypeNew medical document
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionDocument that the requested therapy is effective for the relevant diagnosis and that its dose, frequency, and duration are supported by at least one authoritative source.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical document establishes cerliponase alfa as potentially medically necessary for pediatric patients with neuronal ceroid lipofuscinosis type 2 and unproven for all other non-FDA-approved indications.

    CLN2 diseaseCovered disease indication
    PediatricCovered population
    All other non-FDA-approved indicationsUnproven uses
    300 mg every other weekDose and frequency

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J0567
    Listed billing code

    Coverage Criteria

    Medical Necessity and Evidence

    Coverage requires that the requested therapy meet all of the following medical-necessity and evidence requirements:

    ALL of the following

    • The requested therapy is proven effective for the relevant diagnosis or procedure.
    • For drug therapy, the proposed dose, frequency, and duration are consistent with recommendations in at least one authoritative source, such as FDA-approved labeling, nationally recognized drug compendia, peer-reviewed scientific literature, generally accepted standards of medical care, professional society guidelines, or CMS coverage policy.

    Ohio Statutory Off-Label Coverage

    For members residing in Ohio, coverage of an FDA-approved drug for an off-label use may be required when all of the following criteria are met, subject to the member contract and applicable state requirements:

    ALL of the following

    • The member resides in Ohio and the applicable group or individual policy covers prescription drugs.
    • The drug is approved by the U.S. Food and Drug Administration.
    • The drug is prescribed for an indication not approved by the FDA but recognized as safe and effective in one or more standard medical reference compendia adopted by the U.S. Department of Health and Human Services or in medical literature.
    • ONE of the following evidence pathways

      • The proposed off-label use is recognized as safe and effective in one or more applicable standard medical reference compendia.
      • Medical literature pathway

        • Safety and efficacy for the proposed off-label use are confirmed in two articles from major peer-reviewed professional medical journals that present data supporting the use as generally safe and effective.
        • The supporting literature uses an acceptable study design, which may include randomized, double-blind, placebo-controlled clinical trials.
        • The evidence is not limited to case studies or case series.

    Medically Necessary Indication

    Cerliponase alfa (Brineura™) may be considered medically necessary when all of the following are met:

    ALL of the following

    • The patient is a pediatric patient.
    • The patient has neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 deficiency.
    • Treatment is intended to slow the loss of ambulation.

    Initial Therapy

    Initial coverage may be provided when all of the following FDA-labeled indication criteria are met:

    ALL of the following

    • The patient has CLN2 disease, a specific form of Batten disease, also known as late-infantile neuronal ceroid lipofuscinosis type 2 or tripeptidyl peptidase-1 deficiency.
    • The patient is a child of any age, including symptomatic or presymptomatic patients.
    • Cerliponase alfa is prescribed to slow the loss of walking ability (ambulation).

    Covered Indication

    Coverage is supported for the following medically necessary indication:

    ALL of the following

    • The requested drug is cerliponase alfa (Brineura™).
    • The patient is a pediatric patient with neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 deficiency.
    • Treatment is intended to slow the loss of ambulation.

    The Ohio off-label coverage exception does not require coverage when the FDA has recognized the use as contraindicated. Coverage is also not required for non-formulary drugs.

    Cerliponase alfa (Brineura™) is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.

    Brineura is not recommended for patients less than 37 weeks post-menstrual age or those weighing less than 2.5 kg because physiologic immaturity may increase the risk of serious and clinically significant adverse reactions. Post-menstrual age is gestational age at birth plus post-natal age.

    Indications for cerliponase alfa that are not approved by the U.S. Food and Drug Administration are considered experimental, investigational, and unproven.

    HCPCS Coding

    HCPCS CodesHCPCS
    J0567HCPCS code listed for cerliponase alfa

    Provider Documentation and Authorization Actions

    Documentation Required

    Evidence and Regimen Requirements

    The requested therapy must be proven effective for the relevant diagnosis. For drug therapy, the proposed dose, frequency, and duration must be consistent with recommendations from at least one authoritative source.

    • Submit evidence supporting effectiveness for the requested diagnosis.
    • Support the proposed dose, frequency, and duration with FDA-approved labeling, a nationally recognized drug compendium, professional society guideline, peer-reviewed literature, or another authoritative reference.
    Documentation Required

    Clinical Evidence and Dosing Support

    Provide clinical documentation that supports both the expected treatment benefit and the proposed Brineura regimen. The request should identify the applicable FDA labeling or authoritative clinical evidence and include the prescribed dose, frequency, infusion details, and duration of therapy.

    • Document the diagnosis and clinical rationale for treatment to slow loss of ambulation.

    Policy Background

    Medical policies are based on generally accepted standards of care and authoritative clinical references, including drug compendia, professional guidelines, peer-reviewed literature, and CMS coverage policy. Requested drug therapy must be supported by evidence of effectiveness and by an authoritative recommendation for the proposed dose, frequency, and duration.

    Definitions

    Neuronal ceroid lipofuscinosis type 2
    ConditionNeuronal ceroid lipofuscinosis type 2 is a pediatric disease for which cerliponase alfa may be used to slow the loss of ambulation.
    Alternate designationAlso known as tripeptidyl peptidase 1 deficiency.
    Covered populationPediatric patients with neuronal ceroid lipofuscinosis type 2.
    Neuronal ceroid lipofuscinosis type 2 disease (CLN2)
    Disease typeAn autosomal recessive inherited lysosomal storage disorder.
    Enzyme deficiencyCaused by deficient tripeptidyl peptidase-1 (TPP1).
    Clinical effect

    Initial Therapy Criteria

    Initial Therapy Evidence

    Initial coverage requires evidence supporting the requested therapy and regimen:

    General drug-therapy requirements

    • The requested therapy is proven effective for the relevant diagnosis or procedure.
    • The proposed dose, frequency, and duration are consistent with recommendations in at least one authoritative source.

    FDA-Labeled Indication

    Coverage is based on the FDA-labeled indication:

    Initial cerliponase alfa therapy

    • Confirmed disease: The patient has CLN2 disease or tripeptidyl peptidase-1 deficiency.

    Quantity and Administration Limits

    Cerliponase alfa (Brineura)
    Dose300 mg.
    FrequencyEvery other week.
    AdministrationBy intraventricular infusion.
    Brineura (cerliponase alfa)
    Quantity300 mg.
    ScheduleEvery other week.
    RouteBy intraventricular infusion.

    Site of Care and Administration

    Note

    Use the required outpatient infusion setting

    Administer Brineura by infusion into the cerebrospinal fluid through a surgically implanted intraventricular access device in a hospital outpatient setting. Administration must be under the supervision of a physician experienced in intraventricular administration, including management of hypersensitivity reactions, and is followed by an infusion of intraventricular electrolytes.

    Note

    Administer by intraventricular infusion

    The clinical study administered Brineura by intraventricular infusion. Ensure the hospital outpatient administration method uses intraventricular infusion as specified by the policy.

    Policy Summary
    PayerHealthSpring
    PolicyCerliponase alfa
    Policy CodePolicy RX501.092
    Change TypeNew medical document
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionDocument that the requested therapy is effective for the relevant diagnosis and that its dose, frequency, and duration are supported by at least one authoritative source.
    SourceLink
    On This Page
    Coverage CriteriaHCPCS CodingProvider Documentation and Authorization ActionsPolicy BackgroundDefinitionsInitial Therapy CriteriaQuantity and Administration LimitsSite of Care and Administration
  1. Include the proposed dose, frequency, duration, infusion rate or other regimen details, and the source supporting each element.
  2. Refer to current FDA guidance for dosage, volume, infusion rate, contraindications, warnings, and precautions.
  3. Documentation Required

    Confirm CLN2 Diagnosis

    Establish that the member has CLN2 disease, also known as neuronal ceroid lipofuscinosis type 2 or tripeptidyl peptidase-1 deficiency, using accepted diagnostic testing and clinical documentation.

    • Provide deficient TPP1 enzyme activity demonstrated in an accepted sample type, such as leukocytes, dried blood spots, fibroblasts, or saliva, with normal control-enzyme activity when applicable.
    • Support the diagnosis with molecular analysis showing one pathogenic TPP1/CLN2 mutation on each parental allele when available.
    • Document whether the disease is symptomatic or presymptomatic and the patient's age.
    Denial Risk

    Ohio Statutory Limitations

    For members residing in Ohio, coverage may be required for an FDA-approved drug used for an off-label indication only when the use is recognized as safe and effective in an adopted standard medical compendium or qualifying medical literature. Coverage is not required when the FDA has recognized the use as contraindicated or for non-formulary drugs.

    • For off-label use supported by medical literature, provide two articles from major peer-reviewed professional medical journals confirming safety and efficacy; case studies or case series alone are insufficient.
    • Check the member contract and applicable state requirements before applying this exception.
    Denial Risk

    FDA-Approved Indication Required

    Cerliponase alfa (Brineura) may be considered medically necessary only for its FDA-approved indication: slowing loss of ambulation in pediatric patients with CLN2 disease, also known as tripeptidyl peptidase-1 deficiency.

    • Document that the requested use is to slow loss of ambulation in a child with CLN2 disease.
    • Requests for a use outside the FDA-approved indication may be denied unless applicable state law or the member contract requires otherwise.

    Unsupported block type: denial_risk כר?

    Unsupported block type: denial_risk

    Results in progressive neurologic deterioration.
    Tripeptidyl peptidase-1 (TPP1)
    RoleTripeptidyl peptidase-1 (TPP1) is the deficient enzyme associated with CLN2 disease.
    Testing sampleTPP1 enzyme activity can be assessed in leukocytes or dried blood spots.
    Additional testing samplesTPP1 enzyme activity can also be assessed in fibroblasts or saliva.
    Post-menstrual age
    DefinitionPost-menstrual age is gestational age at birth plus post-natal age.
    First componentGestational age at birth.
    Second componentPost-natal age.
    CLN2 Clinical Rating Scale Motor domain
    Scale rangeThe CLN2 Clinical Rating Scale Motor domain ranges from 3 to 0.
    Score meaningsA score of 3 means grossly normal; a score of 0 means profoundly impaired.
    Defined declineDecline is an unreversed (sustained) 2-category decline or an unreversed score of 0 in the Motor domain.
    CLN2 disease
    Primary nameCLN2 disease is neuronal ceroid lipofuscinosis type 2.
    Alternate nameAlso known as tripeptidyl peptidase 1 deficiency.
    Treatment contextCerliponase alfa is FDA-approved to slow the loss of ambulation in pediatric patients with CLN2 disease.
  4. Age and disease status: The patient may be of any age and may be symptomatic or presymptomatic.

    The FDA indication includes children of all ages, whether symptomatic or presymptomatic.

  5. Therapeutic purpose: Treatment is intended to slow the loss of ambulation.
  6. FDA-Approved Indication

    Cerliponase alfa may be considered medically necessary for the FDA-approved indication:

    Initial therapy

    • Patient population: The patient is pediatric.
    • Diagnosis: The patient has neuronal ceroid lipofuscinosis type 2, also known as tripeptidyl peptidase 1 deficiency.
    • Treatment purpose: Treatment is intended to slow the loss of ambulation.

      The policy is based on the FDA-labeled indication.